These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 37597246)
1. Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer. Van Cutsem E; Yaeger R; Delord JP; Tabernero J; Siu LL; Ducreux M; Siena S; Elez E; Kasper S; Zander T; Steeghs N; Murphy D; Edwards M; Wainberg ZA Oncologist; 2023 Dec; 28(12):e1209-e1218. PubMed ID: 37597246 [TBL] [Abstract][Full Text] [Related]
2. REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer. Nakajima H; Kotani D; Bando H; Kato T; Oki E; Shinozaki E; Sunakawa Y; Yamazaki K; Yuki S; Nakamura Y; Yamanaka T; Yoshino T; Ohta T; Taniguchi H; Kagawa Y BMC Cancer; 2021 Jun; 21(1):674. PubMed ID: 34098908 [TBL] [Abstract][Full Text] [Related]
3. Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. Napolitano S; De Falco V; Martini G; Ciardiello D; Martinelli E; Della Corte CM; Esposito L; Famiglietti V; Di Liello A; Avallone A; Cardone C; De Stefano A; Montesarchio V; Zampino MG; Bordonaro R; Scartozzi M; Santini D; Di Maio M; De Vita F; Altucci L; Marrone F; Ciardiello F; Troiani T JAMA Oncol; 2023 Jul; 9(7):966-970. PubMed ID: 37200022 [TBL] [Abstract][Full Text] [Related]
4. Multicentre single-arm phase II trial evaluating the safety and effiCacy of Panitumumab and iRinOtecan in NeoRAS Wild-type mEtaStatic colorectal cancer patientS (C-PROWESS trial): study protocol. Osumi H; Ishizuka N; Takashima A; Kumekawa Y; Nakano D; Shiozawa M; Denda T; Sawada R; Ouchi K; Wakatsuki T; Narikazu B; Kato K; Yamaguchi K; Shinozaki E BMJ Open; 2022 Sep; 12(9):e063071. PubMed ID: 36581973 [TBL] [Abstract][Full Text] [Related]
5. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Sartore-Bianchi A; Pietrantonio F; Lonardi S; Mussolin B; Rua F; Crisafulli G; Bartolini A; Fenocchio E; Amatu A; Manca P; Bergamo F; Tosi F; Mauri G; Ambrosini M; Daniel F; Torri V; Vanzulli A; Regge D; Cappello G; Marchiò C; Berrino E; Sapino A; Marsoni S; Siena S; Bardelli A Nat Med; 2022 Aug; 28(8):1612-1618. PubMed ID: 35915157 [TBL] [Abstract][Full Text] [Related]
6. Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes. Bekaii-Saab TS; Lach K; Hsu LI; Siadak M; Stecher M; Ward J; Beckerman R; Strickler JH Oncologist; 2023 Oct; 28(10):885-893. PubMed ID: 37463037 [TBL] [Abstract][Full Text] [Related]
7. Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer. Kim TW; Elme A; Park JO; Udrea AA; Kim SY; Ahn JB; Valencia RV; Krishnan S; Manojlovic N; Guan X; Lofton-Day C; Jung AS; Vrdoljak E Clin Colorectal Cancer; 2018 Sep; 17(3):206-214. PubMed ID: 29703606 [TBL] [Abstract][Full Text] [Related]
8. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial. Watanabe J; Muro K; Shitara K; Yamazaki K; Shiozawa M; Ohori H; Takashima A; Yokota M; Makiyama A; Akazawa N; Ojima H; Yuasa Y; Miwa K; Yasui H; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Hihara M; Soeda J; Misumi T; Yamamoto K; Akagi K; Ochiai A; Uetake H; Tsuchihara K; Yoshino T JAMA; 2023 Apr; 329(15):1271-1282. PubMed ID: 37071094 [TBL] [Abstract][Full Text] [Related]
9. Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in Townsend A; Tebbutt N; Karapetis C; Cooper P; Singhal N; Yeend S; Pirc L; Joshi R; Hardingham J; Price T Clin Cancer Res; 2018 Aug; 24(16):3838-3844. PubMed ID: 29739790 [No Abstract] [Full Text] [Related]
10. Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer. Alshammari K; Aung KL; Zhang T; Razak ARA; Serra S; Stockley T; Wang L; Nguyen J; Spreafico A; Hansen AR; Zwir D; Siu LL; Bedard PL Clin Colorectal Cancer; 2021 Dec; 20(4):334-341. PubMed ID: 34417144 [TBL] [Abstract][Full Text] [Related]
11. Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition. Rimassa L; Bozzarelli S; Pietrantonio F; Cordio S; Lonardi S; Toppo L; Zaniboni A; Bordonaro R; Di Bartolomeo M; Tomasello G; Dadduzio V; Tronconi MC; Piombo C; Giordano L; Gloghini A; Di Tommaso L; Santoro A Clin Colorectal Cancer; 2019 Jun; 18(2):125-132.e2. PubMed ID: 30846365 [TBL] [Abstract][Full Text] [Related]
12. Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell-free DNA. Watanabe J; Maeda H; Nagasaka T; Yokota M; Hirata K; Akazawa N; Kagawa Y; Yamada T; Shiozawa M; Ando T; Kato T; Mishima H; Sakamoto J; Oba K; Nagata N Int J Cancer; 2022 Dec; 151(12):2172-2181. PubMed ID: 35723084 [TBL] [Abstract][Full Text] [Related]
13. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Fornaro L; Lonardi S; Masi G; Loupakis F; Bergamo F; Salvatore L; Cremolini C; Schirripa M; Vivaldi C; Aprile G; Zaniboni A; Bracarda S; Fontanini G; Sensi E; Lupi C; Morvillo M; Zagonel V; Falcone A Ann Oncol; 2013 Aug; 24(8):2062-7. PubMed ID: 23666916 [TBL] [Abstract][Full Text] [Related]
14. A comparison of panitumumab and cetuximab in the treatment of KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Liu T; Jiang S; Teng X; Zhong L; Liu M; Jin Y; Dong M Immunopharmacol Immunotoxicol; 2023 Feb; 45(1):1-9. PubMed ID: 35950851 [TBL] [Abstract][Full Text] [Related]
17. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis. Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682 [TBL] [Abstract][Full Text] [Related]
18. The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. Battaglin F; Schirripa M; Buggin F; Pietrantonio F; Morano F; Boscolo G; Tonini G; Lutrino ES; Lucchetti J; Salvatore L; Passardi A; Cremolini C; Arnoldi E; Scartozzi M; Pella N; Boni L; Bergamo F; Zagonel V; Loupakis F; Lonardi S BMC Cancer; 2018 Jan; 18(1):98. PubMed ID: 29370781 [TBL] [Abstract][Full Text] [Related]
19. Tumour location and efficacy of first-line EGFR inhibitors in Benavides M; Díaz-Rubio E; Carrato A; Abad A; Guillén C; Garcia-Alfonso P; Gil S; Cano MT; Safont MJ; Gravalos C; Manzano JL; Sánchez A; Alcaide J; López R; Massutí B; Sastre J; Martínez E; Escudero P; Méndez M; Aranda E ESMO Open; 2019; 4(6):e000599. PubMed ID: 31803504 [TBL] [Abstract][Full Text] [Related]
20. Negative Hyperselection of Patients With Morano F; Corallo S; Lonardi S; Raimondi A; Cremolini C; Rimassa L; Murialdo R; Zaniboni A; Sartore-Bianchi A; Tomasello G; Racca P; Clavarezza M; Adamo V; Perrone F; Gloghini A; Tamborini E; Busico A; Martinetti A; Palermo F; Loupakis F; Milione M; Fucà G; Di Bartolomeo M; de Braud F; Pietrantonio F J Clin Oncol; 2019 Nov; 37(33):3099-3110. PubMed ID: 31539295 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]